◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Indoco Remedies Limited (INDOCO) Financial History

Name: Indoco Remedies Limited (INDOCO) financial statement history
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Drug Manufacturers - Specialty & Generic · DATA UPDATED 2026-11-03

Indoco Remedies Limited (INDOCO) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Mumbai, India with about 6,000 employees. Its market capitalization is roughly ₹20 billion. In the fiscal year ended 2026-03-31, INDOCO reported ₹17.9B in revenue and (₹951M) in net income.

Indoco Remedies Limited manufactures and markets formulations and active pharmaceutical ingredients in India and internationally.

Interactive charts & full statements → Open the INDOCO valuation workbench →

INDOCO Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-09-30	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Total Revenue	₹18.6B	₹17.9B	₹16.4B	₹17.9B	₹16.4B	—
Gross Profit	₹12.6B	₹12.3B	₹11.3B	₹12.1B	₹11.0B	—
Operating Income (EBIT)	₹352M	(₹190M)	(₹267M)	₹1.4B	₹2.0B	—
Net Income	₹319M	(₹951M)	(₹737M)	₹985M	₹1.4B	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

INDOCO Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-09-30	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-03-31
Total Revenue	₹5.1B	₹4.7B	₹4.6B	₹4.3B	₹4.7B	—
Gross Profit	₹3.3B	₹3.1B	₹3.1B	₹3.1B	₹3.3B	—
Operating Income (EBIT)	₹120M	₹65M	₹172M	(₹5M)	₹108M	—
Net Income	₹184M	₹650M	(₹216M)	(₹298M)	(₹79M)	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

INDOCO Free Cash Flow History

Cash flow	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Dividends Paid	(₹19M)	(₹139M)	(₹207M)	(₹207M)	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

INDOCO Balance Sheet History

Balance sheet	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Total Assets	₹25.9B	₹24.3B	₹21.4B	₹16.6B	—
Total Liabilities	₹16.6B	₹14.1B	₹10.3B	₹6.3B	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive INDOCO viewer.

Other Companies in Drug Manufacturers - Specialty & Generic

FREDUN · Fredun Pharmaceuticals Limited — ₹24 billion
6887 · Sunshine Lake Pharma Co., Ltd. — HK$24 billion
1513 · Livzon Pharmaceutical Group Inc. — HK$21 billion
2929 · Pharma Foods International Co., Ltd. — JPY 20 billion
SAKAR · Sakar Healthcare Limited — ₹20 billion
HESTERBIO · Hester Biosciences Limited — ₹19 billion
SYNCOMF · Syncom Formulations (India) Limited — ₹19 billion
0013 · HUTCHMED (China) Limited — HK$18 billion

← INDOBORAX All “I” companies INDOFARM →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.